Annual report [Section 13 and 15(d), not S-K Item 405]

Summary of Significant Accounting Policies - Segment Information Significant Expense Categories (Details)

v3.26.1
Summary of Significant Accounting Policies - Segment Information Significant Expense Categories (Details)
12 Months Ended
Dec. 31, 2025
USD ($)
segment
Dec. 31, 2024
USD ($)
Segment Information    
Number of reportable segments | segment 1  
Operating expenses:    
Total research and development $ 21,866,071 $ 3,530,913
General and administrative expenses 6,102,374 8,696,335
Total operating expenses 27,968,445 12,227,248
Loss on debt conversion with related party 6,134,120  
Loss on fixed asset disposal 2,731  
Exchange loss, net 27,916 30,787
Net loss before income taxes 34,257,370 12,349,724
Single reportable segment    
Operating expenses:    
Acquired in-process research and development 12,030,389  
Clinical 7,251,179 1,153,345
Chemical, manufacturing and controls 1,027,799 710,055
Research and preclinical 58,198 505,750
Regulatory 43,477 20,065
Other research and development costs 1,455,029 1,141,698
Total research and development 21,866,071 3,530,913
General and administrative expenses 6,102,374 8,696,335
Total operating expenses 27,968,445 12,227,248
Loss on debt conversion with related party 6,134,120  
Interest (income) expense, net (96,938) 92,192
Loss on fixed asset disposal 2,731  
Exchange loss, net 27,916 30,787
Net loss before income taxes $ 34,036,274 $ 12,350,227